Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling

Pharmacometric covariate analyses support both mechanistic understanding and clinical decision-making, that is, two different objectives which require different analysis targets. Adopting the ICH E9(R1) estimand framework clarifies this distinction, reconciling mechanistic modeling (conditional covariate effects) with regulatory and clinical needs (unconditional covariate effects), clarifying that estimand definition, i.e. the objective, and not the estimator, is the first choice to make in covariate modeling. This structured approach optimizes quantitative evidence for communicating clinical impact and patient care.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2026-04-01
DOI
https://doi.org/10.1002/psp4.70251
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling

E. Niclas Jonsson, France Mentré, Joakim Nyberg
CPT Pharmacometrics & Systems Pharmacology
Statistical Methods in Clinical Trials
article

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling

E. Niclas Jonsson, France Mentré, Joakim Nyberg
article en

Abstract

Pharmacometric covariate analyses support both mechanistic understanding and clinical decision-making, that is, two different objectives which require different analysis targets. Adopting the ICH E9(R1) estimand framework clarifies this distinction, reconciling mechanistic modeling (conditional covariate effects) with regulatory and clinical needs (unconditional covariate effects), clarifying that estimand definition, i.e. the objective, and not the estimator, is the first choice to make in covariate modeling. This structured approach optimizes quantitative evidence for communicating clinical impact and patient care.

CPT Pharmacometrics & Systems PharmacologyVol. 15(4)
Délégation Paris 5 (FR), Inserm (FR), Université Paris Cité (FR), Sorbonne Paris Cité (FR)
Peace, Justice and strong institutions
Openalex Percentile: Top 20%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.